Impact of genetic variation in the vasopressin 1a receptor on the development of organ failure in patients admitted for acute decompensation of liver cirrhosis by Kerbert, A.J.C. et al.
Impact of genetic variation in the vasopressin 1a
receptor on the development of organ failure in
patients admitted for acute decompensation of liver
cirrhosis
Annarein J.C. Kerberta,*, Jelte J. Schaapmana,*, Johan J. van der Reijdena, Àlex Amorós Navarrob,
Aiden McCormickf, Bart van Hoeka, Vicente Arroyoc, Pere Ginèsc, Rajiv Jalane, Victor Vargasd, Rudolf Stauberg,
Hein W. Verspageta and Minneke J. Coenraada; for the CANONIC Study Investigators of the EASL-CLIF
Consortium
Background Vasopressin receptor-mediated vasoconstriction is considered to be involved in the pathogenesis of organ failure
in acute-on-chronic liver failure (ACLF).
Patients and methods We studied the association between six single nucleotide polymorphisms (SNPs) of the vasopressin 1a
receptor gene and the development of organ failure in 826 patients admitted for acute decompensation of liver cirrhosis (n=641)
or ACLF (n=185).
Results No associations were found for SNPs with the presence of circulatory or renal failure. A C> T mutation in SNP
rs7308855 and a T>A mutation in SNP rs7298346 showed an association with the presence of coagulation failure in the entire
population (n=61, P=0.024 and 0.060, respectively) and in the subgroup of patients with ACLF (n= 44, P= 0.081 and 0.056,
respectively).
Conclusion Genetic variation in the vasopressin 1a receptor was found not to be associated with circulatory or renal failure, but
with the presence of coagulation failure in patients with acute decompensation of liver cirrhosis and ACLF. Eur J Gastroenterol
Hepatol 29:535–538
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Introduction
Acute decompensation of liver cirrhosis (AD) is defined as
the acute development of one or more complications of the
underlying liver disease. Acute-on-chronic liver failure
(ACLF) is a distinct syndrome from AD as it is associated
with the presence of organ failure, high short-term mortality
rates, age, and precipitating events [1]. Systemic inflamma-
tion seems to play a key role in the development of ACLF.
Also, systemic hemodynamic dysfunction and the activation
of endogenous vasoconstrictor systems are believed to be
involved in the pathogenesis [2]. A decreased systemic
vascular resistance leads to the activation of compensatory
vasoconstrictor systems and the nonosmotic release of
arginine vasopressin (AVP) [3,4]. AVP is a neurohypophy-
seal hormone that plays a prominent role in the cardio-
vascular system and mediates vascular smooth muscle
contraction through the V1a receptor (AVP1aR) [5]. A
previous study has found an association between single
nucleotide polymorphisms (SNPs) in the promotor region of
AVP1aR and the presence of essential hypertension in
nonobese Japanese patients [6]. Considering the important
role of AVP1aR in regulating vascular tone and baror-
eceptor sensitivity [7], we hypothesized that heterogeneity in
AVP1aR may affect the risk of developing renal and cir-
culatory failure in cirrhotic patients. This may be relevant
information in clinical practice as patients with certain
genotypes of AVP1aR may need more intensive surveillance
and treatment. The aim of this study was to investigate
whether genetic variation of AVP1aR is associated with the
presence of circulatory failure, renal failure and outcome in
cirrhotic patients with AD and ACLF.
Patients and methods
Patients
This study is an ancillary study of the prospective, obser-
vational CANONIC study [1]. In that study, 1343 patients
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hospitalized for AD of cirrhosis were included between
February and September 2011. The HCB-IDIBAPS
Biobank in Barcelona (Spain) manages the CANONIC
database and storage of biomaterials. The study protocol
conformed to the ethical guidelines of the 1975
Declaration of Helsinki (6th revision, 2008). Initially, we
carried out a pilot study including 188 patients from the
CANONIC database without (n=93) and with ACLF
(n=95). These samples were centrally randomly selected
as stratified groups by the HCB-IDIBAPS Biobank per-
sonnel, who were not involved in this study. On the basis
of these preliminary results, the study population was
extended involving all 826 CANONIC patients who pro-
vided informed consent for isolation and storage of
genomic DNA for future research. ACLF and individual
organ failures were defined using the CLIF-Organ Failure
score [8]. This scoring system is a simplification of the
CLIF-sequential Organ Failure Assessment scale, which
was developed by the CANONIC study for defining and
diagnosing organ failure in cirrhotic patients. The CLIF-
Organ Failure score involves a total of six organ systems
(i.e. liver, kidney, brain, coagulation, circulation and
respiration). For each system, three subscores have been
defined: subscore 1= normal or moderate organ dysfunc-
tion, subscore 2=marked organ dysfunction, and subscore
3=organ failure. According to the CLIF-Organ Failure
score, the following criteria are defined for individual
organ failures: liver failure=bilirubin≥12mg/dl; kidney
failure= creatinine≥2 and <3.5 mg/dl (subscore 2) or
creatinine≥3.5 mg/dl or renal replacement (subscore 3);
cerebral failure=West-Haven grade 3–4; coagulation
failure= international normalized ratio (INR)≥ 2.5; cir-
culatory failure=use of vasopressors; and respiratory
failure= PaO2/FiO2 ratio≤200 or SpO2/FiO2 ratio≤ 214.
Patient characteristics and clinical data were retrieved
from the CANONIC database.
Genotyping
For genetic testing, DNA was isolated from 10ml EDTA
blood of each patient with consent for genetic testing.
DNA samples were stored at − 80°C. Genotyping was
performed in the Leiden University Medical Centre,
Leiden, the Netherlands. Six SNPs of AVP1aR with
potential clinical relevance were identified from pre-
liminary studies [6,9]. The genotype of rs7298346 was
identified by PCR with allele-specific amplification pri-
mers. Genotypes of the other five variants were identified
by PCR, followed by restriction fragment length poly-
morphism. PCR was performed in a 25 µl reaction volume
containing 50 ng DNA, ReddyMix (Thermo Scientific,
Waltham, Massachusetts, USA) and 0.24 µmol/l of each
primer. Restriction enzymes (New England BioLabs,
Ipswich, Massachusetts, USA) used to determine the gen-
otypes were BfaI, MLuCI, PstI, Tsp45I and Sau3AI for
rs113481894, rs11174817, rs7308855, rs1042615 and
rs10747983, respectively. The DNA fragments were
separated by electrophoresis on a 2.5% agarose gel and
visualized by staining with ethidium bromide. The inves-
tigators were blinded to the clinical outcomes during the
determination of genotypes of the AVP1a receptor gene.
Statistical analysis
For all SNPs, deviation from Hardy–Weinberg equilibrium
was calculated using Pearson’s χ2-test. The association
between SNPs and the presence of ACLF, individual organ
failures and levels of relevant laboratory values were
evaluated using Fisher’s exact test. A Cox proportional
hazard regression analysis was carried out to assess the
relation of SNPs with overall survival in all patients and in
the subgroup of patients with ACLF.
Results
In the pilot study (n=188), an association for a T>A
mutation in rs7298346 and, to a lesser extent, for a C>T
mutation in rs7308855 with the presence of renal failure at
the time of hospital admission was found in patients with
ACLF (n=64, P= 0.025 and 0.103, respectively). The
same mutations showed significant associations with lower
90-day survival in all patients (hazard ratio= 1.81, 95%
confidence interval= 1.02–3.23, P= 0.044 and hazard
ratio=2.17, 95% confidence interval= 1.17–4.01,
P= 0.013, respectively). No association was found
between SNPs and the presence of circulatory failure.
Patient characteristics of the entire cohort study at time
of hospital admission for AD of cirrhosis (n=641) or
ACLF (n=185) are shown in Table 1. All SNPs were in
Hardy–Weinberg equilibrium, except for rs10747983
(P<0.05). In contrast to the results of the pilot study, no
association was found between the studied SNPs and the
presence of renal failure or 90-day survival. Moreover, no
association was found between SNPs and the presence of
ACLF (Table 1) or single circulatory, liver, cerebral or
respiratory failure. When comparing patients with CLIF-
Organ Failure subscore 1 (normal or moderate organ
dysfunction) versus 2 (marked organ dysfunction) or 3
(organ failure), no associations between SNPs and these
organ functions were found either.
Instead, a C>T mutation in SNP rs7308855 showed a
significant association with the presence of ‘coagulation
failure’ (defined as INR≥2.5 according to the CLIF-Organ
Failure score) in cirrhotic patients admitted with AD or
ACLF (Table 2) and showed a clear trend towards the
presence of coagulation failure in the subgroup of patients
with ACLF (n=44, P=0.081). A trend was also found for
a T>A mutation in SNP rs7298346 to be associated with
the presence of coagulation failure in the entire study
population (Table 2) and in the subgroup of patients with
ACLF (P=0.056). When comparing patients with CLIF-
Organ Failure subscore 1 (n= 643) versus 2 and 3
(n=170), the same mutations in these SNPs were more
frequently present in patients with subscore 2 or 3 com-
pared with patients with subscore 1 (P=0.050 and 0.055,
respectively). Despite the association found for a mutation
in SNP rs7308855 and rs7298346 with coagulation fail-
ure, the median values of markers of coagulation function
(INR, prothrombin time, activated partial thromboplastin
time and platelet count) did not differ significantly between
patients with or without a mutation in these SNPs.
Finally, no association was found between the SNPs
studied and survival after 28 days and 3, 6 and 12 months
of follow-up.
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Discussion
The results of the present study suggest that there is a weak
association between two of the studied SNPs of AVP1aR
with an INR of at least 2.5 in patients admitted for AD of
cirrhosis or ACLF. No associations with SNPs were found
with the presence of other types of organ failure.
AVP1aR is expressed widely and is involved in diverse
functions including vascular smooth muscle contraction
[10]. The presence of peripheral vasodilation contributes
towards the development of portal hypertension in cir-
rhosis. The subsequent activation of endogenous vaso-
constrictor systems, such as AVP, plays a role in the
development of ascites, hyponatraemia and hepatorenal
syndrome [1,3]. In ACLF, activation of these vasocon-
strictor systems is considered to contribute towards the
pathogenesis [2]. Because of its prominent role in the
cardiovascular system, we hypothesized that genetic het-
erogeneity in AVP1aR might be involved in the develop-
ment of organ failure in cirrhosis, especially in circulatory
and renal failure. The present study is the first to investi-
gate the implication of AVP1aR SNPs in recognizing cir-
rhotic patients with AD who are at risk of developing
(multi)organ failure.
We did not find an association with AVP1aR SNPs and
the presence of ACLF, the majority of individual organ
failures (i.e. renal, liver, circulatory, respiratory and cere-
bral failure) and outcome in the entire study cohort.
Instead, an association was found between mutations in
rs7308855 and rs7298346 and the presence of coagulation
failure, which was defined as an INR of at least 2.5. Our
observation of discrepancy between the results of the
hypothesis-driven pilot study and the full cohort study
once more underlines that the results obtained in such a
relatively small sample size pilot study, using stratified
groups of patients, do not allow to draw firm conclusions,
in our case on possible associations and trends between
SNPs in AVP1aR and the development of renal failure and
90-day survival.
AVP1aR is expressed on the platelet membrane and is
involved in the coagulation cascade [11]. Stimulation of
AVP1aR activates the phosphatidyl inositol cascade,
leading to an increase in cytoplasmatic calcium and sti-
mulation of platelet formation and aggregation [12,13]. It
has been shown previously that there is significant het-
erogeneity in the aggregation response of normal human
platelets to AVP. The authors of that study hypothesized
that this variability in aggregation response might be
related to a SNP in AVP1aR [14]. A more recent study
investigated the association between four SNPs in the
promotor region of AVP1aR and platelet vasopressin
responsiveness [15]. No significant associations were
found in that study. There are no data available on the
effect of heterogeneity of the thrombocyte aggregation
response in cirrhosis. Coagulopathy is a major concern in
chronic liver failure. Cirrhotic patients are at an increased
risk of bleeding because of portal hypertension and syn-
thetic dysfunction of the liver. Increased bleeding tendency
Table 1. Baseline characteristics and distributions of six variants of







(n=641) ACLF (n=185) P-value
Age (years) 57.6 ±11.8 57.7 ± 12.1 57.4 ±11.0 0.752
Male sex 525 (63.6) 405 (63.2) 120 (64.9) 0.675
Aetiology of cirrhosis
Alcohol 490 (60.0) 363 (57.3) 127 (69.4) 0.003
HBV 39 (5.0) 33 (5.5) 6 (3.4) 0.266
HCV 253 (32.4) 203 (33.7) 50 (28.3) 0.176
NAFLD 39 (5.0) 28 (4.7) 11 (6.3) 0.389
PBC 22 (2.8) 18 (3.0) 4 (2.3) 0.628
Cryptogenic 50 (6.4) 42 (7.0) 8 (4.6) 0.247
Other 52 (6.7) 44 (7.3) 8 (4.6) 0.202
Organ failures at baseline
Liver 116 (14.0) 42 (6.6) 74 (40.0) <0.001
Kidney 109 (13.2) – 109 (58.9) –
Cerebral 49 (5.9) 15 (2.3) 34 (18.4) <0.001
Coagulation 61 (7.4) 17 (2.7) 44 (23.8) <0.001
Respiration 18 (2.2) 4 (0.6) 14 (7.6) <0.001
Circulation 34 (4.1) 4 (0.6) 30 (16.2) <0.001
Laboratory data
INR 1.5 (1.3–1.8) 1.5 (1.3–1.7) 1.8 (1.4–2.4) <0.001
PT (s) 19 (16–26) 18 (16–25) 23 (17–32) 0.016
APTT (s) 1.5 (1.2–31) 1.4 (1.2–30) 1.9 (1.3–37) 0.002
Platelet count
(×109/l)
86 (55–137) 89 (56–139) 75 (51–121) 0.019
Bilirubin
(mg/dl)
3.0 (1.6–6.9) 2.8 (1.5–5.5) 6.7 (2.0–16.7) <0.001
Creatinine
(mg/dl)
1.0 (0.7–1.4) 0.9 (0.7–1.2) 2.2 (1.0–3.1) <0.001
Sodium
(mmol/l)
135 ±6 135 ± 6 134 ±7 0.009
CRP (mg/l) 18 (7–40) 15 (6–35) 27 (12–53) <0.001
WBC (×109/l) 6.0 (4.1–9.2) 5.7 (4.0–8.3) 7.7 (5.3–12.3) <0.001
Genetic variants of AVP1aR
Rs113481894
CC 697 (82.5) 528 (82.8) 151 (81.6) 0.720
CT/TT 144 (17.5) 110 (17.2) 34 (18.4)
Rs7298346
TT 635 (77.0) 497 (77.7) 138 (74.6) 0.384
TA/AA 175 (21.2) 143 (22.3) 47 (25.4)
Rs11174817
AA 223 (27.1) 167 (26.1) 56 (30.3) 0.265
AG/GG 601 (72.9) 472 (73.9) 129 (69.7)
Rs1042615
AA 129 (15.6) 99 (15.5) 30 (16.2) 0.805
AG/GG 696 (84.4) 541 (84.5) 155 (83.8)
Rs10747983
GG 136 (72.3) 69 (74.2) 67 (70.5) 0.574
GC/CC 52 (27.7) 24 (25.8) 28 (29.5)
Rs7308855
CC 692 (84.0) 541 (84.7) 151 (81.6) 0.321
CT/TT 132 (16.0) 98 (15.3) 34 (18.4)
Results are described as n (%), mean ±SD or median (interquartile range).
ACLF, acute-on-chronic liver failure; APTT, activated partial thromboplastin time;
AVP1aR, vasopressin 1a receptor; CRP, C-reactive protein; HBV, hepatitis B virus;
HCV, hepatitis C virus; INR, international normalized ratio; NAFLD, nonalcoholic
fatty liver disease; PBC, primary biliary cholangitis; PT, prothrombin time; WBC,
white blood cell count.
Table 2. The association of a mutation in two single nucleotide
polymorphisms in the vasopressin 1a receptor gene with the presence of
coagulation failure (international normalized ratio≥2.5) in cirrhotic patients








CC 647 (84.8) 45 (73.8)
CT/TT 116 (15.2) 16 (26.2)
rs7298346 0.060
TT 594 (77.8) 41 (67.2)
TA/AA 170 (22.5) 20 (32.8)
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in cirrhosis is associated with an increased risk of mor-
bidity and mortality in patients undergoing invasive pro-
cedures. In cirrhotic patients with sepsis, a common
feature in ACLF, haemostasis seems to be even further
impaired [16]. Therefore, identification of cirrhotic
patients who are at an increased risk of bleeding might be
beneficial for developing treatment and prevention strate-
gies for these patients. However, further research in even
larger cohorts of cirrhotic patients is needed to validate the
results and to explore the pathophysiological mechanisms.
The fact that markers of coagulation function were not
different in patients with or without a mutation in
rs7308855 and rs7298346 suggests that associations with
coagulation failure found in the current study are rather
indirect and not functionally reflected.
It is also important to consider that the definition of
coagulation failure used in this study (INR≥2.5) only
represents the extrinsic pathway of the coagulation cas-
cade. Furthermore, changes in INR are multifactorial. A
more specific definition considering the function of the
complete coagulation system should be applied in future
studies.
We conclude that six SNPs of AVP1aR may not be
useful as genetic markers to identify cirrhotic patients with
AD who are at an increased risk of developing ACLF.
However, an association of two genotypes (rs7308855 and
rs7298346) with coagulation failure in patients with AD
of cirrhosis or ACLF was found, which requires further
functional evaluation.
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